Deucravacitinib
Deucravacitinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against non-receptor tyrosine-protein kinase TYK2. In addition, it is known to target tyrosine-protein kinase JAK1 and bone morphogenetic protein receptor type-2.
| Trade Name | |
|---|---|
| Common Name | Deucravacitinib |
| Indication | |
| Drug Class | Tyrosine kinase inhibitors: janus kinase inhibitors; deuterated compounds |
